Drug Profile


Alternative Names: ICX-RHY-013; Vavelta

Latest Information Update: 08 Jul 2016

Price : $50

At a glance

  • Originator Intercytex
  • Class Fibroblast cell therapies; Skin disorder therapies
  • Mechanism of Action Collagen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity No

Highest Development Phases

  • Suspended Scars
  • No development reported Epidermolysis bullosa

Most Recent Events

  • 06 Jul 2016 ICX RHY licensed to Knight Therapeutics for marketing in Canada, Israel, Russia and sub-Saharan Africa, Romania and the Caribbean
  • 16 Mar 2016 Ember Therapeutics acquires ICX RHY from Intercytex
  • 19 Feb 2016 ICX-RHY is available for licensing as of 19 Feb 2016. http://www.intercytex.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top